Phaseline

Companies › Shanghai Bao Pharmaceuticals

Shanghai Bao Pharmaceuticals: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 2; Genitourinary, Other.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
KJ101
Enzymatic debriding agent
–Phase 2Burn–
KJ103 for Injection–Phase 2Anti-Glomerular Basement Membrane Disease–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06607016KJ103 for InjectionPhase 2Anti-Glomerular Basement Membrane DiseaseGenitourinaryDec 2025
NCT07025408KJ101Phase 2BurnOtherMar 2026

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Akebia Therapeutics Angitia Zynerba Pharmaceuticals Juro Sciences

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.